Document jy2GJ81V7g1RxMDwrz0pQ0Bx5

The Cosmetic, Toiletry and Fragrance Association, Inc. 1133 15th STREET, N.W.. WASHINGTON, D.C. 30005 202/331-1770 TELEX 89-2673 James H. PMWeirWrit-t7f NorWmeantF. Estrin. Ph D. MINUTES CTFA TALC TASK FORCE A meeting of the CTFA Talc Task Force was held or March 11th, 1976 at the CTFA offices in Washington, D.C. Those in attendance were: Gfeorge Sand land, Bristol-Myers Company (Chairman) John E. Clements, Pfizer, Inc. Ray Krammer, Whittaker, Clark & Daniels George Lee, Johnson .& Johnson Baby Products Company Monroe Messinger, Chesehrouqh-Pend's Inc. Roderick . Mundy , Sterling Drug Inc. Louis D. Murino, Cyprus Industrial Minerals Company D.R Petterson, Johnson & Johnson Baby Products Company Fred Roesch, Whittaker, Clark & Daniels Robert Rolle, Johnson & Johnson Baby Products Company J ohn P. Schelz, Johnson J o h n s o n Baby Products company Maurice Siegel, Fabrge, Inc. J.C. Simko, Jr., Colgate-Palmolive Company Harold Stanley, Pfizer, Inc. Ian Stewart, Walter C> Mcfone Associates. Robert Suffis, The Mennen Company S, Thompson, R.T. Vanderbilt & Company J o h n J. Travers, Avon Products, Inc. W i l l i a m C. Waggoner, Johnson & Johnson Baby Products Comoar.y Norman F. strin, CTFA Mr. Sandldnd opened the meeting and proceeded with th agenda. 1. Status Review A. Talc Standards and Methods Copies of th proposed specification and methods, plus copis of a letter to Dr. Schaffner trere distributed to task force members. B. A status report (dated March 8th, .1976), prepared by Dt* Petterson, on cosmetic talc states was distributed to those present.* a copy of an article by; CONTINUED ON NEXT PAGE Dr. Rqhl and Dr., Arthur M. Langer on "Identification and Quantitation of Asbestos in Talc" was distributed as it appears in Environmental Health Perspectives, Volume 9, 1974, pp. 95-109. Also, a copy of the correction to the March 8,.1976 Washington Post article on talc and the summary of the-draft Talk Paper anticipated from the FDA was distributed to those present. C. LOwin Samples Mr, Sandland summarized the contents of the November, 1975 letter from Henry Davis (FDA) requesting CTFA apply its methodology to several of Dr. Lewin samples provided on a coded basis. The results of the analyses were described bv Dr. Rolle. 2. Mt. Sinai Analyses on Old Production Samples Dr. Fetter soil gave detailed background o n Dr. Danger's work. He stated the objective of the task force should he to de velop and collate data that would lead to a presentation before the Miscellaneous External Panel, in order to attempt to have talc placed in Category I. The results of Dr. Pooler's analyses., sponsored b y Johnson & Johnson, were summarized. It was reported that Dr. Langer performed his anaylses on sam ples purchased in 1973. Mr. Simko described a meeting be tven himself and Dr. Langer on Tuesday. He estimated the samfle of "Cashmere Bououet" tested was probably a tre-1970 sample. Mr. Mundy (Sterling) reported on his contacts with Dr. Lancer and stated the Sample Dr. Langer tested was from 1970 production. 3. Recent Production Data It was agreed by the task force that it would be extremely beneficial if induvidual companies could provide data to the FDA on recent production. Most companies present indicated that they possess such data and would be willing to provide the data. Mr. Massinger (Cbesebrough-Pond's) stated ho would have to confirm this willingness with his management. It was suggested each company prepare a letter, addressed to Dr. Estrin, with a summary of the data on recent production for their products and a commitment to set-up a subsequent m e eting w i t h FDA- to discuss this data, in ditail, if FDA so desires. This letter should be delivered to Dr. Estrin by Monday, March 15th. Subsequently, a meeting was set-up for that Monday, March 15th, at the CTFA offices, with a meeting at FDA to be held in the afternoon. 4. CTFA S t u d y on Current.Production- A dvantages and disadvantages of having cTFA iror.tr act an in dependent laboratory to do tests on current production sam ples was discussed. It was noted that such data would no doubt be useful, not only in discussions with FDA, but t_lso as part of a presentation to the Miscellaneous External Panel nd, perhaps, to other panels as well, it was suggested the CTFA m e t h o dology be utilized for such a task, but tha*- TEM be used on those samples that have been shown to be positive COfiTINPED ON NEXT PAGE BCST # LEWIN f PRODUCT 1338 1339 1340 13.41 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 7? 77 96 97 VQ1 102A 143 144B 151 154 T57A 160 163 75 173A Lady Ester Face Powder. Rachel Touch and Glow Face Powder Blanchard's Dusting Powder Born Wild Dusting Powder, Del Labs Tai Winds Spray Talc, Avon Tosca Dusting Powder Pin-Zow TaVque, Perf. Beauty Prod. Overton's ."High Brown" Face Powder Early American Old Spice Talcum Powder Bismoline Medicated Powder Mavis. Imported Talcum Avon Beauty Dust Refill Charisma Pinaud Clubman Talc OH 1 de London Talc, Yardley Coreage Dusting Powder TREHOUTE u w i r r DCST X-RAY <0M)___ CHRYSOTHE lETTr~~ ' DCST X-RAY ND 3 8 f 12 15 10 5 5 ND 2 6 ND 10 ND ND 2,800 f / m g , ND 5,600 NO 13,000 10 60,000 15 8,900 NO 1 ,800 7 400 10 ND ? 2,000 ND 9,000 ND ND 8 9,000 trace ? 10 - ND ND 7 ND ? - ND NO ND - ND ~ ND ND - ? ? by CTFA methodology and also be performed on a random basis on other'samples. Company representatives were polled at this meeting and previously by Mr. George Lee to determine whether they would be willing 0 participate in such n study by assur ing that current production samples would be provided and that financial support would be given. The results would be made known to the FDA and probably published in some form. The following companies indicated they would be wxlling to parti cipate: A v o n P r o d u c t s , Inc. Bristol-Myers Company Colgate-Palmolive Company C o t y , 'Inc. Faberge, Inc. Johnson & Johnson Mennen Sterling In addition, Chesebrough-Pond's, Mem, and Yardley would probably be interested. The task force agreed to await the results of the meetinas with CTFA before deciding on whether a study on current produc tion should be initiated. The meeting adjourned in order for a small group to meet with FDA at 2:00 p.m. to discuss the results of CTFA analyses of Dr. Lewin's samples, /P tM dU ofman F. Estrin, Ph.D. / * Vice President - Science NFE:.jj March 12th, 1976